PPPNCT07373535
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: May 2026 to Dec 2026
- Eligibility criteria expanded, about 29 words
- Primary completion pushed from Jul 2028 to Dec 2028
- Secondary endpoints: details revised at 22 of 22 entries
- Notable Start date: Jan 2026 to May 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Enrollment Feasibility
Timeframe: From screening through enrollment
Overall Trial Completion Feasibility
Timeframe: From enrollment through the end of active treatment (Week 10)
Trial Completion by Preference Assignment
Timeframe: From enrollment through the end of active treatment (Week 10)
Distribution of Treatment Preferences
Timeframe: Baseline
Ease of Delivering Treatment Approaches as Assessed by the NASA-TLX
Timeframe: End of each psilocybin treatment session (Week 3, Week 9)
Theoretical Framework of Acceptability (TFA)
Timeframe: Baseline, Weeks 3 and 9 (treatment sessions), Week 11 (follow-up)
Secondary (22)
Rate of Adverse Events in Music- versus Mindfulness-centered Interventions
Rate of Adverse Events in Preferred vs. Non-Preferred Interventions
Rate of Participant Drop-Outs in Preferred vs. Non-Preferred Interventions
Rate of Participant Drop-Outs in Music- versus Mindfulness-centered Interventions
Change From Baseline in MADRS Total Score to Key Endpoint
Show 17 moreShow less
Change From Baseline in BDI-II Total Score to Key Endpoint
Change From Baseline in GAD-7 Total Score to Key Endpoint
Change From Baseline in the 5-level EQ-5D version (EQ-5D-5L) Score to Key Endpoint
Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) Total Score to Key Endpoint
Change From Baseline in Work and Social Adjustment Scale (WSAS) Total Score to Key Endpoint
Change From Baseline in Gratitude Questionnaire-Six Item Form (GQ-6) Total Score to Key Endpoint
Change From Baseline in Multidimensional Psychological Flexibility Inventory (MPFI-24) Total Score to Key Endpoint
Change From Baseline in Watts Connectedness Scale (WCS) Total Score to Key Endpoint
Change From Baseline in Pearlin Mastery Scale Total Score to Key Endpoint
Semi-structured Qualitative Interviews
Challenging Experience Questionnaire Brief (CEQ-7)
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ-SF)
Imprinting (Self-constructed)
Mystical Experience Questionnaire Brief (MEQ-4)
Awe Experience Scale - Short Form (AWE-SF)
Modified Psychedelic Communitas Scale
Psychedelic Music Questionnaire Short-Form (PMQ-SF)
Arms and interventions
Preferred treatmentExperimental
Non-preferred treatmentExperimental
Drugs: Psilocybin 25mg
Other: Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy
Sites
2 sites in 1 country